Rising burden of enterococcal bacteremia in Victoria, Australia: population-based incidence and antimicrobial resistance trends from three decades of surveillance

Enterococcal bacteremia is a common healthcare-associated infection, associated with significant morbidity and mortality, with the emergence of vancomycin-resistant enterococci further complicating treatment and clinical outcomes. Despite this, long-term estimates of population-based incidence and antimicrobial resistance trends are limited. We aim to describe the burden of enterococcal bacteremia in Victoria, Australia (population 7.0 million), over a 35-year period. We conducted a retrospective analysis of laboratory-confirmed enterococcal bacteremia episodes voluntarily reported to the Victorian Hospital Pathogen Surveillance Scheme database from 1988 to 2022. Population-based incidence was estimated using inverse probability weighting to adjust for inconsistent hospital participation. Incidence per 10,000 hospital admissions was determined for the period 2011-2022. Antimicrobial resistance was calculated as the annual proportion of resistant isolates among all tested isolates. Overall, 11,157 enterococcal bacteremia episodes were identified, mainly <i>Enterococcus faecalis</i> (<i>n</i> = 6,915, 61.9%) and <i>Enterococcus faecium</i> (<i>n</i> = 3,558, 31.9%). Incidence increased from <3 episodes/100,000 population in 1988 to >10 by 2022. Incidence per 10,000 hospital admissions within Victoria has also increased from 2.8 in 2011 to 4 in 2022. Although <i>E. faecalis</i> remained mostly susceptible to tested antibiotics, <i>E. faecium</i> showed persistently high levels of vancomycin resistance, ranging from 50.7% (<i>n</i> = 69/136) to 66.5% (<i>n</i> = 139/209) over the past decade. Increasing incidence and high rates of vancomycin resistance among <i>E. faecium</i> highlight the ongoing clinical and public health challenge posed by enterococcal bacteremia. Applying statistical modeling to account for variability in hospital participation improves the certainty of incidence measures and strengthens the evidence for true increase in disease burden.

Authors

Institutions

Publication Details

Journal
Antimicrobial Agents and Chemotherapy
Published
2026-02-04
DOI
https://doi.org/10.1128/aac.01526-25
Primary Topic
Antimicrobial Resistance in Staphylococcus
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rising burden of enterococcal bacteremia in Victoria, Australia: population-based incidence and antimicrobial resistance trends from three decades of surveillance

Patiyan Andersson, Jeremy D. Silver, Courtney R. Lane, Mark Veitch et al.
Antimicrobial Agents and Chemotherapy
Antimicrobial Resistance in Staphylococcus
article

Rising burden of enterococcal bacteremia in Victoria, Australia: population-based incidence and antimicrobial resistance trends from three decades of surveillance

Patiyan Andersson, Jeremy D. Silver, Courtney R. Lane, Mark Veitch, Wendy Siryj, Norelle Sherry, Benjamin P. Howden, Oscar C. Howden, Marwa Talat Alhothali
article en

Abstract

Enterococcal bacteremia is a common healthcare-associated infection, associated with significant morbidity and mortality, with the emergence of vancomycin-resistant enterococci further complicating treatment and clinical outcomes. Despite this, long-term estimates of population-based incidence and antimicrobial resistance trends are limited. We aim to describe the burden of enterococcal bacteremia in Victoria, Australia (population 7.0 million), over a 35-year period. We conducted a retrospective analysis of laboratory-confirmed enterococcal bacteremia episodes voluntarily reported to the Victorian Hospital Pathogen Surveillance Scheme database from 1988 to 2022. Population-based incidence was estimated using inverse probability weighting to adjust for inconsistent hospital participation. Incidence per 10,000 hospital admissions was determined for the period 2011-2022. Antimicrobial resistance was calculated as the annual proportion of resistant isolates among all tested isolates. Overall, 11,157 enterococcal bacteremia episodes were identified, mainly <i>Enterococcus faecalis</i> (<i>n</i> = 6,915, 61.9%) and <i>Enterococcus faecium</i> (<i>n</i> = 3,558, 31.9%). Incidence increased from <3 episodes/100,000 population in 1988 to >10 by 2022. Incidence per 10,000 hospital admissions within Victoria has also increased from 2.8 in 2011 to 4 in 2022. Although <i>E. faecalis</i> remained mostly susceptible to tested antibiotics, <i>E. faecium</i> showed persistently high levels of vancomycin resistance, ranging from 50.7% (<i>n</i> = 69/136) to 66.5% (<i>n</i> = 139/209) over the past decade. Increasing incidence and high rates of vancomycin resistance among <i>E. faecium</i> highlight the ongoing clinical and public health challenge posed by enterococcal bacteremia. Applying statistical modeling to account for variability in hospital participation improves the certainty of incidence measures and strengthens the evidence for true increase in disease burden.

Antimicrobial Agents and ChemotherapyVol. 70(3)
The University of Melbourne (AU), Peter Doherty Institute (AU), Genomics (United Kingdom) (GB), Statistical Research (United States) (US)
Good health and well-being
Openalex Percentile: Top 65%
Antimicrobial Resistance in Staphylococcus
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.